The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1188-1194.e3, December 2009

Adrenergic β2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol

  • Kaninika Basu, MBBS

      Affiliations

    • Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom
    • Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • These authors contributed equally to this work.
    • ,
  • Colin N.A. Palmer, PhD

      Affiliations

    • Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • These authors contributed equally to this work.
    • ,
  • Roger Tavendale, PhD

      Affiliations

    • Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • ,
  • Brian J. Lipworth, FRCP, MD

      Affiliations

    • Asthma and Allergy Research Group, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • ,
  • Somnath Mukhopadhyay, FRCPCH, PhD

      Affiliations

    • Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom
    • Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • Corresponding Author InformationReprint requests: Somnath Mukhopadhyay, FRCPCH, PhD, Royal Alexandra Children's Hospital, Brighton BN2 5BE, United Kingdom.

Received 24 December 2008; received in revised form 30 June 2009; accepted 24 July 2009. published online 05 October 2009.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  Support for the study was approved by the Gannochy Trust (Perth, Scotland), Scottish Enterprises Tayside, and the Perth and Kinross Council. C. N. A. P. is supported by the Scottish Executive Genetic Health Initiative Award.

     Disclosure of potential conflict of interest: B. J. Lipworth has provided consulting advice regarding the fluticasone/formoterol combination for Mundipharma, provided a speakers' bureau talk on budesonide formoterol for AstraZeneca and a speakers' bureau talk on heterogeneity in asthma and airway remodeling for Merck, has received research support from Merck Sharpe & Dohme and Neolab, and has provided legal consultation on formoterol equivalence for TEVA. S. Mukhopadhyay has served as an expert advisor for and received research support from Merck Sharpe & Dohme. The rest of the authors have declared that they have no conflict of interest.

    PII: S0091-6749(09)01150-6

    doi:10.1016/j.jaci.2009.07.043

    The Journal of Allergy and Clinical Immunology
    Volume 124, Issue 6 , Pages 1188-1194.e3, December 2009